Marco A. Maurtua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marco A. Maurtua has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Andrew Zura
Department of General Anesthesiology and Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
2 shared publicationsArmin Schubert
2 shared publicationsMichelle Lotto
2 shared publicationsA. Torres
1 shared publicationAli Rezai
1 shared publicationAnupa Deogaonkar
1 shared publication
Latest Publications
- 1 August 2012
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 24 (5) , 370-372
Use of the CTrach Laryngeal Mask Airway in adult patients: a retrospective review of 126 cases
- 1 August 2012
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 24 (5) , 370-372
Use of the CTrach Laryngeal Mask Airway in adult patients: a retrospective review of 126 cases
- 1 February 2011
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 58 (4) , 409-410
The use of the CTrachTM Laryngeal Mask Airway in pediatric patients: a retrospective review of 25 cases
- 1 February 2011
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 58 (4) , 409-410
The use of the CTrachTM Laryngeal Mask Airway in pediatric patients: a retrospective review of 25 cases
- 1 May 2009
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 21 (3) , 213-216
Dexmedetomidine for deep brain stimulator placement in a child with primary generalized dystonia: case report and literature review
- 1 May 2009
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 21 (3) , 213-216
Dexmedetomidine for deep brain stimulator placement in a child with primary generalized dystonia: case report and literature review
- 1 October 2008
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 17 (4) , 370-373
Anesthetic management of an obstetric patient with MELAS syndrome: case report and literature review
- 1 October 2008
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 17 (4) , 370-373
Anesthetic management of an obstetric patient with MELAS syndrome: case report and literature review
- 1 October 2008
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 20 (4) , 221-225
Dosing of Remifentanil to Prevent Movement During Craniotomy in the Absence of Neuromuscular Blockade
In neuroanesthesia practice, muscle relaxants may at times need to be avoided to facilitate intraoperative motor pathway monitoring. Our study's objective was to determine the optimal dose of remifentanil required to prevent movement after neurosurgical stimulation. After Institutional Review Board approval and written informed consent, 132 patients undergoing elective craniotomy randomly received one of 12 remifentanil dose regimens (0.10 to 0.21 microg/kg/min). Remifentanil was started before induction with propofol and succinylcholine. Anesthesia was maintained with isoflurane (0.6% end-tidal) in air/oxygen. During the study, movement was assessed on predetermined criteria by the anesthesiology, nursing, and neurosurgical teams. Heart rate and blood pressure were recorded every 5 minutes. We assessed the relationship between movement, hypotension, bradycardia, and dose using probit analysis and logistic regression. Sixty-five percent of the patients moved in response to surgical stimuli [95% confidence interval (CI): 49%-79%] at a remifentanil infusion rate of 0.10 microg/kg/min, and movement decreased to 21% (95% CI: 11-35) at 0.21 microg/kg/min. The probability of movement was 50% at an infusion rate (95% CI) of 0.13 (0.10 to 0.15) microg/kg/min remifentanil and decreased to 25% at an infusion rate of 0.19 (0.17 to 0.29) microg/kg/min. The probability of hypotension and bradycardia was 50% at 0.13 (0.10 to 0.15) microg/kg/min and 0.17 (0.15 to 0.21) microg/kg/min, respectively. Higher doses of remifentanil lessen the risk of movement in the absence of muscle relaxants with surgical stimulation for elective craniotomy. Hypotension and bradycardia were common at higher doses. Even at the maximum dose (0.21 mcg/kg/min) there was a 20% chance of movement. Adjunctive therapy is needed to ablate movement reliably, and to counteract the hypotensive effect of remifentanil. These findings may be helpful for clinicians administering remifentanil and isoflurane during procedures, where muscle relaxants may not be desirable.
- 1 October 2008
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 20 (4) , 221-225
Dosing of Remifentanil to Prevent Movement During Craniotomy in the Absence of Neuromuscular Blockade
In neuroanesthesia practice, muscle relaxants may at times need to be avoided to facilitate intraoperative motor pathway monitoring. Our study's objective was to determine the optimal dose of remifentanil required to prevent movement after neurosurgical stimulation. After Institutional Review Board approval and written informed consent, 132 patients undergoing elective craniotomy randomly received one of 12 remifentanil dose regimens (0.10 to 0.21 microg/kg/min). Remifentanil was started before induction with propofol and succinylcholine. Anesthesia was maintained with isoflurane (0.6% end-tidal) in air/oxygen. During the study, movement was assessed on predetermined criteria by the anesthesiology, nursing, and neurosurgical teams. Heart rate and blood pressure were recorded every 5 minutes. We assessed the relationship between movement, hypotension, bradycardia, and dose using probit analysis and logistic regression. Sixty-five percent of the patients moved in response to surgical stimuli [95% confidence interval (CI): 49%-79%] at a remifentanil infusion rate of 0.10 microg/kg/min, and movement decreased to 21% (95% CI: 11-35) at 0.21 microg/kg/min. The probability of movement was 50% at an infusion rate (95% CI) of 0.13 (0.10 to 0.15) microg/kg/min remifentanil and decreased to 25% at an infusion rate of 0.19 (0.17 to 0.29) microg/kg/min. The probability of hypotension and bradycardia was 50% at 0.13 (0.10 to 0.15) microg/kg/min and 0.17 (0.15 to 0.21) microg/kg/min, respectively. Higher doses of remifentanil lessen the risk of movement in the absence of muscle relaxants with surgical stimulation for elective craniotomy. Hypotension and bradycardia were common at higher doses. Even at the maximum dose (0.21 mcg/kg/min) there was a 20% chance of movement. Adjunctive therapy is needed to ablate movement reliably, and to counteract the hypotensive effect of remifentanil. These findings may be helpful for clinicians administering remifentanil and isoflurane during procedures, where muscle relaxants may not be desirable.
- Open Access
- 1 March 2007
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 106 (3) , 640-641
Improving Intubation Success Using the CTrach Laryngeal Mask Airway™
- 1 March 2007
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 106 (3) , 640-641
Open AccessImproving Intubation Success Using the CTrach Laryngeal Mask Airway™